Diabetes treatment guidelines shift toward organ protection

New clinical consensus from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) marks a fundamental shift in Type 2 diabetes management. The updated guidelines move away from a focus solely on glycemic control, instead treating Type 2 diabetes as a systemic disease affecting the heart, kidneys, and liver.

A central recommendation is the earlier use of organ-protective drug classes, specifically SGLT2 inhibitors and GLP-1-based therapies. For many patients, these may be recommended starting at the time of initial diagnosis, depending on individual risk profiles, body weight, and comorbidities. In cases of high cardiovascular risk or established heart and kidney disease, a combination of both drug classes is advised, regardless of HbA1c levels.

While Metformin remains significant, it is no longer strictly required as the first line of treatment if targeted organ protection is necessary. A stepwise approach is now only considered appropriate for patients with low cardiovascular risk and no existing organ damage.

In related clinical developments, biotechnology company AdipoPharma has commenced a Phase 1b study for PATAS, a first-in-class insulin sensitizer. This randomized, double-blind, placebo-controlled trial focuses on multiple ascending doses (MAD) in patients with Type 2 diabetes to evaluate safety, tolerability, and pharmacokinetics, with data readout expected in 2027.